FDA Toughens Stance On Accentuating Admonition On Propoxyphene Based Pain Relievers
On 7 July, The Food and Drug Administration (FDA) has enunciated that the makers of pain allaying drugs that have propoxyphene as their component must compulsorily underline the probable risk by overuse on the warning label of such medicines. The locally available drugs like Darvon and Darvocet-N are amongst them that come under the scanner from this latest announcement.
The FDA has issued instructions to undertake in-depth research to gauge propoxyphene’s side effects on the heart in addition to the frequency of its prescription in aged patients and its safety details in comparison to other market medicines. The FDA is aware that propoxyphene is usually recommended and has been used since 1957.
The director of FDA- Center for Drug Evaluation and Research, Janet Woodcock has stated that those who seek prescriptions and ailing patients must be made conscious about propoxyphene’s possible hazards, with doctors offering treatment only after proper evaluation of the patient’s past records and the warning label on the medicine.
FDA has refuted an appeal from the Public Citizen Group in regards to the confiscation of propoxyphene from markets stating that in spite of its apprehensions; the plus points of the drug definitely prevail over the potential risks.
Popularity: 1% [?]
